With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration. PHILADELPHIA--(BUSINESS WIRE)-- ...

In children with lupus nephritis, neurological manifestations at the time of kidney biopsy, age, and eGFR predicted greater risk of CKD progression. Investigators have identified predictors of chronic ...

MMF induction is a viable alternative to cyclophosphamide for treating mixed proliferative lupus nephritis in children. Oral mycophenolate mofetil (MMF) is as effective as intravenous cyclophosphamide ...

– FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data – – Gazyva is the only anti-CD20 monoclonal antibody to demonstrate ...

Please provide your email address to receive an email when new articles are posted on . Infections are a “small but increasing” cause of hospitalization in childhood SLE, and account for most ...

Lupus nephritis is a serious complication of lupus that is caused by inflammation of the kidneys. It affects up to 60% of people with lupus and usually occurs within 5 years of diagnosis. If left ...